StreetInsider.com News Articles

Silo Pharma, Inc. (SILO) files for 1.91M share offering by selling stockholders

Fri, 24 Jul 2026 16:08:39 -0400

Silo Pharma, Inc. (NASDAQ: SILO) has filed for up to 1,906,392 share offering by selling stockholders.

Silo Pharma, Inc. (SILO) files for 1.91M share offering by selling stockholders

Fri, 24 Jul 2026 16:08:39 -0400

Silo Pharma, Inc. (NASDAQ: SILO) has filed for up to 1,906,392 share offering by selling stockholders.

Form S-3 Silo Pharma, Inc.

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813558.html

Form S-3 Silo Pharma, Inc.

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813558.html

Silo Pharma plans AI platform launch and advances PTSD drug program

Tue, 21 Jul 2026 08:55:46 -0400

Silo Pharma (NASDAQ: SILO) provided an update on its two development programs, including a planned commercial launch of its artificial intelligence subsidiary and continued regulatory progress on its lead drug candidate for post-traumatic stress disorder.

The company's AI subsidiary, QwikAgents, is completing final platform enhancements ahead of a commercial launch anticipated within the next 90 days. Chief Executive Officer Eric Weisblum said in a statement that the company expects to "commercially launch our enhanced AI agent platform within the next 60 days, positioning the Company to begin generating initial revenue."

On the pharmaceutical side, Silo is advancing SPC-15, a preclinical intranasal therapeutic

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Tue, 21 Jul 2026 08:55:00 -0400

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate

AI agent platform prepares for commercial launch while SPC-15 regulatory program advances

SARASOTA, FLA., July 21, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified AI agent technology and developmental-stage biopharmaceutical company focused on addressing underserved conditions including stress-induced psychiatric disorders and central nervous system (CNS) diseases, today provided an update on commercialization progress for its artificial intelligence subsidiary, QwikAgents, and continued advancement of its lead PTSD

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Tue, 21 Jul 2026 08:55:00 -0400

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate

AI agent platform prepares for commercial launch while SPC-15 regulatory program advances

Form D Silo Pharma, Inc.

Tue, 14 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26768635.html

Form D Silo Pharma, Inc.

Tue, 14 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26768635.html

Silo Pharma subsidiary QwikAgents joins AMD AI developer program

Tue, 14 Jul 2026 08:56:25 -0400

Silo Pharma (Nasdaq: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program.

According to a press release, participation in the program provides access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community.

QwikAgents is developing an AI agent platform intended for individuals, developers, small businesses, and enterprises. The platform is designed to support use cases including research, content generation, scheduling, coding, browser automation, and workflow automation. Starter plans begin at $14 per month, with scalable infrastructure options available for larger workloads.

The platform is being built to

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Tue, 14 Jul 2026 08:55:00 -0400

SARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ AMD AI Developer Program. Participation in the program provides access to AMD Developer Cloud credits, advanced AI development tools, training resources, and a global developer community designed to support and accelerate artificial intelligence innovation.

“Joining the AMD AI Developer Program

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Tue, 14 Jul 2026 08:55:00 -0400

“Joining the AMD AI Developer Program

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Tue, 14 Jul 2026 08:55:00 -0400

“Joining the AMD AI Developer Program

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Tue, 14 Jul 2026 08:55:00 -0400

“Joining the AMD AI Developer Program

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Tue, 14 Jul 2026 08:55:00 -0400

Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Tue, 14 Jul 2026 08:55:00 -0400

Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents

Form 8-K Silo Pharma, Inc. For: Jul 09

Mon, 13 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26759111.html

Form 8-K Silo Pharma, Inc. For: Jul 09

Mon, 13 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26759111.html

CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall

Fri, 10 Jul 2026 09:05:07 -0400

Investing.com - U.S. stock index futures edged lower on Friday as investors consolidated gains following Wall Street’s sharp relief rally, with easing crude oil prices and signs of a possible diplomatic breakthrough between Washington and Tehran helping stabilize broader market sentiment.

By 08:25 ET, S&P 500 Futures was flat, Nasdaq 100 Futures had fallen 0.3%, while Dow Jones Futures were up 0.3%.

Artificial intelligence and software stocks remained in focus, while investors also reacted to regulatory approvals, takeover speculation and fresh capital-raising activity.

Here are some of the biggest premarket U.S. stock movers today: